Oric director granted option for 40,000 shares

Q: What insider transaction did ORIC director Richard A. Heyman report?

Richard A. Heyman reported the grant of a stock option covering 40,000 shares of Oric Pharmaceuticals, Inc. common stock on January 2, 2026.

Q: How do the newly granted ORIC stock options vest?

The filing states that 1/12 of the shares subject to the option vest on each one-month anniversary of January 2, 2026, until all 40,000 shares are vested.

Q: When do Richard A. Heyman’s ORIC stock options expire?

The stock option grant to Richard A. Heyman expires on January 1, 2036, if not exercised earlier according to its terms.

Q: Was this ORIC Form 4 filed for non-derivative or derivative securities?

This Form 4 transaction relates to derivative securities, specifically a stock option (right to buy) covering 40,000 shares of Oric Pharmaceuticals, Inc. common stock.

Oric Pharmaceuticals, Inc. director Richard A. Heyman reported receiving a stock option grant for 40,000 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. director Richard A. Heyman reported receiving a stock option grant for 40,000 shares of common stock. The option has an exercise price of $8.17 per share and expires on January 1, 2036. According to the vesting schedule, 1/12 of the shares under the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. Following this grant, he beneficially owns 40,000 stock options directly.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Heyman Richard A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,000 contracts (Direct)

Footnotes (1)

F1. 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORIC director Richard A. Heyman report?

Richard A. Heyman reported the grant of a stock option covering 40,000 shares of Oric Pharmaceuticals, Inc. common stock on January 2, 2026.

What is the exercise price of the new ORIC stock options?

The stock option granted to Richard A. Heyman has an exercise price of $8.17 per share for Oric Pharmaceuticals, Inc. common stock.

How do the newly granted ORIC stock options vest?

The filing states that 1/12 of the shares subject to the option vest on each one-month anniversary of January 2, 2026, until all 40,000 shares are vested.

When do Richard A. Heyman’s ORIC stock options expire?

The stock option grant to Richard A. Heyman expires on January 1, 2036, if not exercised earlier according to its terms.

How many ORIC derivative securities does the director own after this transaction?

After this transaction, Richard A. Heyman beneficially owns 40,000 stock options for Oric Pharmaceuticals, Inc. common stock, held directly.

Was this ORIC Form 4 filed for non-derivative or derivative securities?

This Form 4 transaction relates to derivative securities, specifically a stock option (right to buy) covering 40,000 shares of Oric Pharmaceuticals, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/06/2026 - 04:46 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last)

(First)

(Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.17	01/02/2026		A		40,000		⁽¹⁾	01/01/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

	/s/ Christian Kuhlen, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR